Literature DB >> 6274961

B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.

T Yokochi, R D Holly, E A Clark.   

Abstract

Two new cell surface antigens expressed on B lymphoblastoid cell lines (B-LCL) were defined with cytotoxic mouse monoclonal antibodies. One marker, BB-1 (for B lymphoblast antigen-1), was detected on human and nonhuman primate B-LCL, Epstein-Barr virus (EBV)-activated B cell blasts, most Burkitt's lymphomas, and Ia+ B lymphoblast-like myelomas. Polyclonal B cell activators such as pokeweed mitogen (PWM) and lipopolysaccharide (LPS) also induced the expression of BB-1 on immunoglobulin (Ig)-positive cells. In contrast, BB-1 could not be detected on normal lymphoid tissues by complement-dependent cytotoxicity and immunofluorescence (IF) assays or by analysis with a fluorescence-activated cell sorter (FACS). T cell blasts, T cell leukemias, and pre-B cell or erythroblastic leukemia cell lines were also BB-1 negative. Of particular interest was the finding that BB-1 was expressed on the Jijoye lymphoma but only marginally on a subline of Jijoye, P3HR-1, that lacks receptors for EBV and produces a defective virus incapable of transforming lymphocytes. A second lymphoblast antigen (LB-1) unlike BB-1, was present on both T and B cell blasts and virus-transformed T- and B-LCL but not on normal lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274961

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

2.  Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade.

Authors:  S Hanabuchi; T Ohashi; Y Koya; H Kato; F Takemura; K Hirokawa; T Yoshiki; H Yagita; K Okumura; M Kannagi
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.

Authors:  J Avila-Cariño; S Torsteinsdottir; B Ehlin-Henriksson; M G Masucci; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Functional properties of human lamina propria T lymphocytes assessed with mitogenic monoclonal antibodies.

Authors:  L Qiao; G Schürmann; M Betzler; S C Meuer
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 5.  CD28/B7 regulation of autoimmune diabetes.

Authors:  K G Herold; D J Lenschow; J A Bluestone
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

6.  Genomic organization of the mouse B-lymphocyte activation antigen B7.

Authors:  A Selvakumar; P C White; B Dupont
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

7.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

Authors:  B D Hock; G C Starling; P B Daniel; D N Hart
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

8.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Authors:  M K Racke; D E Scott; L Quigley; G S Gray; R Abe; C H June; P J Perrin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation.

Authors:  D N Hart; G C Starling; V L Calder; N S Fernando
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

10.  Development of the cell contact-mediated accessory function for T-cell proliferation in a human promyelocytic leukaemia cell line, HL-60, by 1,25-dihydroxyvitamin D3.

Authors:  T Shinbori; M Yamada; K Kakimoto; S Araki; K Onoue
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.